0 93

Cited 0 times in

Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung

 Hee Chul Yang  ;  Hyeong Ryul Kim  ;  Jae Yong Park  ;  Ju Sik Yun  ;  Kook Joo Na  ;  Young Mog Shim  ;  Jhingook Kim  ;  Jong Mog Lee  ;  Moon Soo Kim  ;  Jae Ill Zo  ;  Se Hoon Choi  ;  Dong Kwan Kim  ;  Seong Yong Park  ;  Mi Kyung Bae  ;  Kyung Young Chung  ;  Jin-Haeng Chung  ;  Ho-Young Lee  ;  Soyeon Ahn  ;  Sukki Cho  ;  Kwhanmien Kim  ;  Sanghoon Jheon 
 Annals of Surgical Oncology, Vol.22(12) : 4089-4097, 2015 
Journal Title
 Annals of Surgical Oncology 
Issue Date
PURPOSE: The aim of this retrospective, multicenter study was to develop a recurrence risk-scoring model in patients with curatively resected stage I lung adenocarcinoma (ADC). METHODS: Clinicopathologic and outcome data for a development cohort of 1,700 patients with pathologic stage I ADC from four institutions resected between January 2000 and December 2009 were evaluated. A phantom study was performed for correction of inter-institutional differences in positron emission tomography-standardized uptake value (PET-SUV). A nomogram for recurrence prediction was developed using Cox proportional hazards regression. This model was validated in a cohort of 460 patients in two other hospitals. The recurrence rate was 21.0 % for the development cohort and 22.1 % for the validation cohort. RESULTS: In multivariable analysis, three independent predictors for recurrence were identified: pathologic tumor size (hazard ratio [HR] 1.03, 95 % CI 1.017-1.048; p < 0.001), corrected PET-SUV (HR 1.08, 95 % CI 1.051-1.105; p < 0.001), and lymphovascular invasion (HR 1.65, 95 % CI 1.17-2.33; p = 0.004). The nomogram was made based on these factors and a calculated risk score was accorded to each patient. Kaplan-Meier analysis of the development cohort showed a 5-year recurrence-free survival (RFS) of 83 % (95 % CI 0.80-0.86) in low-risk patients and 59 % (95 % CI 0.54-0.66) in high-risk patients with the highest 30 percentile scores. The concordance index was 0.632 by external validation. CONCLUSIONS: This recurrence risk-scoring model can be used to predict the RFS for pathologic stage I ADC patients using the above three easily measurable factors. High-risk patients need close follow-up and can be candidates for adjuvant chemotherapy.
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실)
Yonsei Authors
정경영(Chung, Kyung Young)
사서에게 알리기
Full Text
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.